bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat
Company profile
Ticker
BVS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Bioventus Inc. • Bioventus LLC • Bioventus Holdings LLC • Bioventus Canada, Ulc • Bioventus Germany GmbH • Bioventus UK, Ltd • Misonix LLC • Misonix OpCo, LLC • Solsys Medical, LLC • Perseus Intermediate, Inc. ...
BVS stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
10 Apr 24
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
8-K
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
12 Mar 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Departure of Directors or Certain Officers
12 Jan 24
S-8
Registration of securities for employees
9 Jan 24
8-K
Bioventus Names Robert Claypoole as President and Chief Executive Officer
21 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
7 Nov 23
Transcripts
BVS
Earnings call transcript
2023 Q4
12 Mar 24
BVS
Earnings call transcript
2023 Q3
7 Nov 23
BVS
Earnings call transcript
2023 Q2
8 Aug 23
BVS
Earnings call transcript
2023 Q1
16 May 23
BVS
Earnings call transcript
2022 Q4
31 Mar 23
BVS
Earnings call transcript
2022 Q3
11 Nov 22
BVS
Earnings call transcript
2022 Q2
11 Aug 22
BVS
Earnings call transcript
2022 Q1
10 May 22
BVS
Earnings call transcript
2021 Q4
10 Mar 22
BVS
Earnings call transcript
2021 Q3
14 Nov 21
Latest ownership filings
4
Mark Leonard Singleton
15 Apr 24
4
Anthony D'Adamio
15 Apr 24
4
KATRINA J CHURCH
15 Apr 24
4
Mark Leonard Singleton
12 Apr 24
4
Anthony D'Adamio
12 Apr 24
4
KATRINA J CHURCH
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
27 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.83 mm | 26.83 mm | 26.83 mm | 26.83 mm | 26.83 mm | 26.83 mm |
Cash burn (monthly) | 854.00 k | 629.58 k | 2.73 mm | 17.41 mm | 2.77 mm | (no burn) |
Cash used (since last report) | 5.67 mm | 4.18 mm | 18.14 mm | 115.65 mm | 18.41 mm | n/a |
Cash remaining | 21.15 mm | 22.64 mm | 8.69 mm | -88.82 mm | 8.42 mm | n/a |
Runway (months of cash) | 24.8 | 36.0 | 3.2 | -5.1 | 3.0 | n/a |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 68 |
Opened positions | 15 |
Closed positions | 22 |
Increased positions | 11 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 92.49 bn |
Total shares | 74.17 mm |
Total puts | 24.50 k |
Total calls | 150.80 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
SNN Smith & Nephew | 22.02 mm | $319.02 mm |
Essex Woodlands Management | 13.02 mm | $37.63 bn |
Ew Healthcare Partners Acquisition Fund | 13.02 mm | $188.68 mm |
Juniper Investment | 6.66 mm | $19.24 bn |
Nantahala Capital Management | 5.62 mm | $16.23 bn |
Spindletop Healthcare Capital | 3.91 mm | $56.60 mm |
AMP-CF | 3.26 mm | $0.00 |
Vanguard | 1.20 mm | $3.45 bn |
Kent Lake Capital | 900.00 k | $2.60 bn |
BLK Blackrock | 469.08 k | $1.36 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Katrina J Church | Class A Common Stock | Sell | Dispose S | No | Yes | 4.75 | 1,325 | 6.29 k | 17,042 |
11 Apr 24 | Anthony D'Adamio | Class A Common Stock | Sell | Dispose S | No | Yes | 4.75 | 3,054 | 14.51 k | 58,242 |
11 Apr 24 | Mark Leonard Singleton | Class A Common Stock | Sell | Dispose S | No | Yes | 4.75 | 4,000 | 19.00 k | 34,665 |
10 Apr 24 | Katrina J Church | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 4,300 | 0.00 | 18,367 |
10 Apr 24 | Katrina J Church | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 4,300 | 0.00 | 12,900 |
10 Apr 24 | Mark Leonard Singleton | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 13,000 | 0.00 | 38,665 |
10 Apr 24 | Mark Leonard Singleton | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 13,000 | 0.00 | 39,000 |
News
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
15 Mar 24
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $9
13 Mar 24
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Mar 24
Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday
12 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Mar 24
Press releases
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
12 Mar 24
INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Bioventus Inc. (NASDAQ: BVS) and Encourages Long-Term Investors to Contact the Firm
14 Feb 24
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
12 Feb 24